{
    "clinical_study": {
        "@rank": "46994", 
        "arm_group": [
            {
                "arm_group_label": "Xeris glucagon", 
                "arm_group_type": "Experimental", 
                "description": "Xeris glucagon 50 micrograms, subcutaneous injection"
            }, 
            {
                "arm_group_label": "Lilly glucagon", 
                "arm_group_type": "Active Comparator", 
                "description": "Lilly glucagon 30 micrograms, subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris\n      Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs.\n      micro-doses of Glucagon for Injection (Eli Lilly)."
        }, 
        "brief_title": "Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 1"
        }, 
        "detailed_description": {
            "textblock": "This study will test the hypothesis that micro-doses of a new formulation of stable\n      glucagon, Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior by pharmacokinetic\n      and pharmacodynamic criteria vs. micro-doses of a freshly reconstituted formulation of\n      glucagon that has poor stability in solution, Glucagon for Injection (Eli Lilly)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 21 to 80 years old  with type 1 diabetes for at least one year.\n\n          -  Diabetes managed using an insulin infusion pump using rapid-acting insulin such as\n             insulin aspart (NovoLog), insulin lispro (Humalog), and insulin glulisine (Apidra)\n             for at least one week prior to enrollment.\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed consent.\n\n          -  Unable to comply with study procedures.\n\n          -  Current participation in another diabetes-related clinical trial that, in the\n             judgment of the principle investigator, will compromise the results of the clamp\n             study or the safety of the subject.\n\n          -  Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the\n             immediate future, or sexually active without use of contraception.\n\n          -  End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).\n\n          -  Hemoglobin < 11.5 gm/dl.\n\n          -  History of pheochromocytoma.  Fractionated metanephrines will be tested in patients\n             with history increasing the risk for a catecholamine secreting tumor (paroxysms of\n             tachycardia, pallor, or headache;  personal or family history of MEN 2A, MEN 2B,\n             neurofibromatosis, or von Hippel-Lindau disease; episodic or treatment of refractory\n             hypertension, defined as requiring 4 or more medications to achieve normotension).\n\n          -  History of adverse reaction to glucagon (including allergy) besides nausea, vomiting,\n             or headache.\n\n          -  Inadequate venous access as determined by study nurse or physician at time of\n             screening.\n\n          -  Liver failure or cirrhosis.\n\n          -  Any other factors that, in the judgment of the principal investigator, would\n             interfere with the safe completion of the study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018627", 
            "org_study_id": "2013P002549"
        }, 
        "intervention": [
            {
                "arm_group_label": "Xeris glucagon", 
                "intervention_name": "Xeris glucagon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lilly glucagon", 
                "intervention_name": "Lilly glucagon", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "bionic pancreas", 
            "artificial pancreas", 
            "insulin", 
            "glucagon", 
            "clamp"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "contact": {
                "email": "cballiro@mgh.harvard.edu", 
                "last_name": "Courtney A Balliro, BS, RN", 
                "phone": "617-726-1242"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Steven J Russell, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon", 
        "overall_contact": {
            "email": "cballiro@mgh.harvard.edu", 
            "last_name": "Courtney A Balliro, BS, RN", 
            "phone": "617-726-1242"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Steven J Russell, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "tmax for Xeris vs. Lilly (non-inferiority)", 
            "measure": "tmax", 
            "safety_issue": "No", 
            "time_frame": "1 day visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018627"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Steven J. Russell, MD, PhD", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)", 
                "measure": "AOCGIR", 
                "safety_issue": "No", 
                "time_frame": "1 day visit"
            }, 
            {
                "description": "Maximal glucose infusion rate (GIRmax) for Xeris vs. Lilly (non-inferiority)", 
                "measure": "GIRmax", 
                "safety_issue": "No", 
                "time_frame": "1 day visit"
            }, 
            {
                "description": "Glucagon t\u00bdmax for Xeris vs. Lilly  (non-inferiority)", 
                "measure": "t\u00bdmax", 
                "safety_issue": "No", 
                "time_frame": "1 day visit"
            }, 
            {
                "description": "Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:\n-Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain", 
                "measure": "Injection pain", 
                "safety_issue": "Yes", 
                "time_frame": "immediately after injection"
            }, 
            {
                "description": "Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:\n-Injection site erythema or other local reaction, maximum diameter within 1 hour of injection", 
                "measure": "Injection site erythema", 
                "safety_issue": "Yes", 
                "time_frame": "within 1 hour of injection"
            }, 
            {
                "description": "Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:\n-Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10", 
                "measure": "Maximal nausea", 
                "safety_issue": "Yes", 
                "time_frame": "within 1 hour of injection"
            }, 
            {
                "description": "Grade on the erythema and eschar formation portion of the Draize scale for dermal response", 
                "measure": "Dermal response (Draize scale for erythema and eschar formation)", 
                "safety_issue": "Yes", 
                "time_frame": "within 1 hour of injection"
            }, 
            {
                "description": "Grade on the edema formation portion of the Draize scale for dermal response", 
                "measure": "Dermal response (Draize scale grade for edema formation)", 
                "safety_issue": "Yes", 
                "time_frame": "within 1 hour of injection"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Steven J. Russell, MD, PhD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}